Trial
NCT00744354
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.
Condition
Multiple Myeloma and Plasma Cell Neoplasm
Intervention
bortezomib
Why stopped
Drugs unavailable- study terminated 1/2/18
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-18